FDA Approves Cablivi for Rare Blood-Clotting Disorder

Share this content:
FDA Approves Cablivi for Rare Blood-Clotting Disorder
FDA Approves Cablivi for Rare Blood-Clotting Disorder

WEDNESDAY, Feb. 6, 2019 (HealthDay News) -- Cablivi (caplacizumab-yhdp) injection has been approved by the U.S. Food and Drug Administration to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP).

"Patients with aTTP endure hours of treatment with daily plasma exchange, which requires being attached to a machine that takes blood out of the body and mixes it with donated plasma and then returns it to the body," Richard Pazdur, M.D., director of the FDA Oncology Center of Excellence, said in a statement. "Even after days or weeks of this treatment, as well as taking drugs that suppress the immune system, many patients will have a recurrence of aTTP."

Cablivi is the first targeted treatment that inhibits blood clot formation and provides a new treatment option for patients that may reduce recurrences. Cablivi was evaluated in clinical studies involving 145 people. Those treated with Cablivi had fewer instances of aTTP-related death, the FDA said.

Common side effects include headache and bleeding of the nose or gums. Cablivi's prescribing information includes a warning about the risk for severe bleeding. Health care providers should closely monitor patients who also take anticoagulants, the FDA said.

The drug is produced by Ablynx, based in Belgium.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Operative Treatment Seems Most Effective for Adult Lumbar Scoliosis

Operative Treatment Seems Most Effective for Adult Lumbar ...

Nonoperative tx advised if patient satisfied with spine-related health; surgery may improve outcomes

Intervention Can Reduce Orders for Inpatient Urine Cultures

Intervention Can Reduce Orders for Inpatient Urine Cultures

Intervention includes notifications to providers, changes to order sets, new urine culture reflex tests

Odds of Receiving Tx for CAD Up With Medicare Advantage

Odds of Receiving Tx for CAD Up With ...

However, no significant difference seen in intermediate outcomes for those enrolled in MA, FFS Medicare

is free, fast, and customized just for you!




Already a member?

Sign In Now »